Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could your blood type predict kidney treatment success?

NCT ID NCT07757269

Knowledge-focused Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This study asks whether a person's ABO/Rh blood type is linked to how well their diabetic kidney disease responds to standard treatment. Researchers will follow 161 adults with type 2 diabetes and kidney disease for one year, measuring kidney function and protein in the urine at the start and end. The goal is to see if certain blood types are associated with better or worse outcomes, which could one day help tailor treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Laboratory measurements of kidney function and blood markers (eGFR, ACR, HbA1c, lipids, electrolytes)
What this could lead to
If blood type is linked to treatment response, doctors might personalize kidney disease care based on a simple blood test.
What could go wrong
This is an observational study, so it can show associations but not prove cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

161 people

The number who actually took part.

Started

May 2024

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

evident diabetic kidney disease defined as persistent albuminuria \[Albumin/ creatinine ration (ACR) \>30 mg/g Creatinine in two measurements with at least a 3-month difference\], reduced eGFR (\<60 mL/min/1.73 m²), or both and a documented history of type 2 diabetes mellitus for more than five years, as well as diabetic retinopathy classified according to the International Clinical Diabetic Retinopathy Scale of the American Academy of Ophthalmology

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years with type 2 DM * Evident diabetic kidney disease * Recorded ABO blood group phenotypes * Receiving Angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blockers (ARBs) in addition Sodium-glucose cotransporter 2 inhibitor (SGLT2i) as part of their ongoing therapy prior to enrolment. Exclusion Criteria: * Pre-existed glomerular diseases or any other primary kidney disorder, * Active urinary sediment * Type 1 diabetes mellitus * Gestational diabetes * History of kidney transplantation * Documented episode of acute kidney injury, * Family history of non-diabetic forms of kidney disease * \>30% declines in eGFR after initiation of RAAS inhibitors

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetic kidney disease impaired renal function disease kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney disease

Contacts and locations

Locations

  • Faculty of medicine

    Cairo, KasrAlainy, 11562, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.